Abstract
Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers. Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas. Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity. Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 382-389 |
| Number of pages | 8 |
| Journal | International Archives of Otorhinolaryngology |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 1 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Otorhinolaryngology
Cite this
Clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck cancer : A systematic review. / Nguyen, Austin; Bhavsar, Sheila; Riley, Erinn; Caponetti, Gabriel; Agrawal, Devendra K.
In: International Archives of Otorhinolaryngology, Vol. 20, No. 4, 01.10.2016, p. 382-389.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck cancer
T2 - A systematic review
AU - Nguyen, Austin
AU - Bhavsar, Sheila
AU - Riley, Erinn
AU - Caponetti, Gabriel
AU - Agrawal, Devendra K.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers. Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas. Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity. Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.
AB - Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers. Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas. Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity. Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.
UR - http://www.scopus.com/inward/record.url?scp=84992133878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992133878&partnerID=8YFLogxK
U2 - 10.1055/s-0036-1583168
DO - 10.1055/s-0036-1583168
M3 - Review article
AN - SCOPUS:84992133878
VL - 20
SP - 382
EP - 389
JO - International Archives of Otorhinolaryngology
JF - International Archives of Otorhinolaryngology
SN - 1809-9777
IS - 4
ER -